Focus: LifeMine Therapeutics is a early-stage biotechnology company founded in 2024, pioneering fungi-derived therapeutic platforms with a focus on immunology. The company has secured Series C+ funding including a recent $263M raise from high-profile backers including Bezos and Gates.
Profile data last refreshed 10h ago · AI intelligence enriched 1w ago
LifeMine is a high-conviction platform bet backed by elite capital and founder credibility, ideal for scientists and developers willing to build from scratch; unsuitable for those seeking established infrastructure or near-term commercial scale.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for LifeMine Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from LifeMine Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
LifeMine Therapeutics Forms Clinical Advisory Board to Advance LIFE-001 Transplant Drug - citybiz
LifeMine Therapeutics Forms Clinical Advisory Board to Advance LIFE-001 Transplant Drug citybiz
LifeMine Therapeutics Forms Clinical Advisory Board of Leading Experts in Organ Transplantation - BioSpace
LifeMine Therapeutics Forms Clinical Advisory Board of Leading Experts in Organ Transplantation BioSpace
Bezos and Gates back AI drug discovery firm LifeMine - Billionaires.Africa
Bezos and Gates back AI drug discovery firm LifeMine Billionaires.Africa
The 50 best-funded biotech companies of 2026 - Drug Discovery & Development
The 50 best-funded biotech companies of 2026 Drug Discovery & Development
LifeMine gets $263m for transplant drug, and other financings - pharmaphorum
LifeMine gets $263m for transplant drug, and other financings pharmaphorum
LifeMine Raises $263 Million to Accelerate the Clinical Development of LIFE-001, a Structurally and Mechanistically Novel Calcineurin Activation Inhibitor Designed to Transform Organ Transplantation - Business Wire
LifeMine Raises $263 Million to Accelerate the Clinical Development of LIFE-001, a Structurally and Mechanistically Novel Calcineurin Activation Inhibitor Designed to Transform Organ Transplantation Business Wire
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo